Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | PAH | P00439 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10481441 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| SCHEMBL10481435 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| Water SCHEMBL10481481 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| SCHEMBL10364107 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| Water SCHEMBL10481474 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| Ammonia Solution, Strong SCHEMBL10906972 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| SCHEMBL11121517 | 0.99 | HPRT1 (0.48) | HPRT1XDHPNPTK1USP2 | |
| SCHEMBL3280693 | 0.89 | HPRT1 (0.50) | HPRT1USP2HSD17B10BLMCASP7 | |
| SCHEMBL2507689 | 0.86 | HPRT1 (0.47) | HPRT1XDHPNPTK1USP2 | |
| SCHEMBL6363806 | 0.85 | HPRT1 (0.48) | HPRT1USP2HSD17B10BLMCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098641-B1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | claimed |
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | claimed |
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | claimed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | claimed |
| US-4857316-A | Synergistic antiviral composition | SYNTEX (U.S.A.) INC. (US) | 1989-08-15 | — | — | US | claimed |
| US-4642346-A | VIRICIDES | SYNTEX (U.S.A.) INC. (US) | 1987-02-10 | — | — | US | claimed |
| US-4606917-A | Synergistic antiviral composition | SYNTEX (U.S.A) INC. (US) | 1986-08-19 | — | — | US | claimed |
| EP-0187702-A1 | N-(omega,omega-1-dialkoxy)- and N-(omega,omega-1-dialkenoxy)-alk-1-yl-N,N,N-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them | SYNTEX (U.S.A.) INC. (US) | 1986-07-16 | — | — | EP | claimed |
| EP-0066208-B1 | 9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)-GUANINE AS ANTIVIRAL AGENT | SYNTEX (U.S.A.) INC. (US) | 1985-10-02 | — | — | EP | claimed |
| US-4507305-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1985-03-26 | — | — | US | claimed |
| EP-0105486-A2 | 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-18 | — | — | EP | claimed |
| US-4423050-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | claimed |
| EP-0066208-A1 | 9-(1,3-Dihydroxy-2-propoxymethyl)-guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-12-08 | — | — | EP | claimed |
| US-4355032-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-10-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | HPRT1 140/4885XDH 523/4885PNP 53/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | HPRT1 308/4885XDH 599/4885PNP 55/4885 |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | IMPDH1, HAVCR2, IMPDH2 | HPRT1 106/4885XDH 366/4885PNP 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.